| Bioactivity | Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer[1][2][3]. |
| Invitro | Nemvaleukin alfa 激活食蟹猴和人类样本的淋巴细胞亚群，EC50s 为 0.45-2.2 nM[2]。Nemvaleukin alfa (0-100 nM，30 分钟) 诱导人细胞 (HH 细胞) 上的中等亲和力 IL-2R 的激活[3]。Nemvaleukin alfa (0-100 nM，30 分钟) 在 NK 细胞中诱导 pSTAT5，EC50 为 0.45 nM[3]。Nemvaleukin alfa (0.5 nM，5 天) 诱导从人外周血中分离的效应淋巴细胞的激活[3]。 |
| In Vivo | Nemvaleukin alfa (6 mg/kg，皮下注射，每 4 天一次) 抑制小鼠 SCLC 肿瘤的生长[1]。 Animal Model: |
| Name | Nemvaleukin alfa |
| CAS | 2315268-27-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pan Y, et al, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913. [2]. Lopes JE, et al. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2021 Nov;379(2):203-210. [3]. Lopes JE, et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673. |